News + Filings IR Vault
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Quarterly results CC transcript Inv. presentation Appointed director Director departure Credit agrmnt [a] Asset disposition Acq. announced Appointed CFO Consulting agrmnt Auditor change Notes underwriting agrmnt Director comp. Employment agrmnt Dividend declared Appointed COO Filed Chapter 11 Monthly dividend Preliminary results Accel. buyback Cert. of designation Acq. completed Monthly oper. report Merger agrmnt [a] Quarterly results presentation Class action filed CFO resigned Departure of a VP SSS news release Asset acq. complete Letter to company Buyback announced Bonus plan approved Upcoming conference date Notes have priced Coll. bargaining agrmnt 10-Q late filing RE purchase Amended bylaws New credit facility
|
All Companies
|
Create: Portfolio | Alert |
All | News | Filings
Date Filed | Symbol | Type | Description |
08/07/2023 |
TSLA
|
8-K
| Appointed CFO |
05/31/2023 |
******
|
8-K
| Appointed CFO
Docs:
|
"EMPLOYMENT AGREEMENT",
"FRESH VINE WINE, INC.",
"FRESH VINE WINE, INC. STOCK OPTION AGREEMENT This Stock Option Agreement is made and entered into as of May 25, 2023 by and between Fresh Vine Wine, Inc., a Nevada corporation , and Hitesh Dheri . Background A. The Company has adopted the Fresh Vine Wine, Inc. 2021 Equity Incentive Plan , to increase stockholder value and to advance the interests of the Company by furnishing a variety of economic incentives designed to attract, retain and motivate employees, certain key consultants and directors of the Company, under which shares of common stock, $0.001 par value per share, of the Company have been reserved for issuance. B. The Company intends to grant stock options to Employee as an inducement material to Employee entering into employment with the Company, pursuant to Section 711 of the N...",
"Agreement" |
|
05/15/2023 |
ROOT
|
8-K
| Appointed CFO |
05/05/2023 |
******
|
8-K
| Appointed CFO |
01/10/2023 |
ALIM
|
8-K
| Appointed CFO
Docs:
|
"Materials”) when acting within the scope of Executive’s employment , or any Assigned Invention cannot be fully made, used, reproduced or otherwise exploited without using or violating any Restricted Materials, Executive hereby grants and agrees to grant to the Company a perpetual, irrevocable, worldwide, royalty-free, non-exclusive, sublicensable right and license to exploit and exercise all such Restricted Materials and intellectual property rights therein. Executive will not use or disclose any Restricted Materials for which Executive is not fully authorized to grant the foregoing license. To the extent allowed by applicable law, the terms of this Section 6 include all rights of paternity, integrity, disclosure and withdrawal and any other rights that may be known as or referred t...",
"Alimera Sciences Appoints Industry Veteran Russell L. Skibsted as Chief Financial Officer" |
|
09/02/2022 |
******
|
8-K
| Appointed CFO |
07/25/2022 |
WWWW
|
8-K
| Quarterly results |
06/30/2022 |
******
|
8-K
| Appointed CFO |
03/30/2022 |
******
|
8-K
| Appointed CFO |
03/23/2022 |
ROOT
|
8-K
| Appointed CFO |
03/16/2022 |
GES
|
8-K
| Appointed CFO, Quarterly results |
01/13/2022 |
******
|
8-K
| Appointed CFO |
12/07/2021 |
INVE
|
8-K
| Quarterly results |
09/10/2021 |
ICCT
|
8-K
| Quarterly results |
08/04/2021 |
FORR
|
8-K
| Appointed CFO |
07/26/2021 |
MGEN
|
8-K
| Appointed CFO
Docs:
|
"Kristian Humer Employment Agreement",
"VIRIDIAN THERAPEUTICS APPOINTS KRISTIAN HUMER AS CHIEF FINANCIAL OFFICER AND CHIEF BUSINESS OFFICER BOULDER, Colo., July 26, 2021 — Viridian Therapeutics, Inc. , a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but underserved by today's therapies, today announced the appointment of Kristian Humer as its new Chief Financial Officer and Chief Business Officer. “Kristian brings extensive global finance experience as our new CFO and CBO. His appointment builds upon the tremendously talented team of executives we've already assembled in recent months, as we advance our pipeline of investigational therapies to address serious diseases with significant unmet medical needs,” commented Jonathan Violin, Ph.D., President and Chief Executive Officer of..." |
|
07/13/2021 |
MITQ
|
8-K
| Appointed CFO
Docs:
|
"Underwriting Agreement between Moving iMage Technologies, Inc. and Boustead Securities, LLC, as representative of the underwriters named therein",
"Representative’ s Warrant",
"Warrant issued to Agility Capital III, LLC",
"Exchange Agreement among the Company, and the Members of Moving iMage Technologies, LLC",
"Trading Expected to Begin Today on NYSE American",
"Moving iMage Technologies, Inc. Announces Closing of Initial Public Offering" |
|
06/23/2021 |
******
|
8-K
| Quarterly results |
06/08/2021 |
TDC
|
8-K
| Quarterly results |
06/07/2021 |
******
|
8-K
| Quarterly results |
04/05/2021 |
AYTU
|
8-K
| Quarterly results |
03/16/2021 |
ICCT
|
8-K
| Quarterly results |
03/15/2021 |
INSU
|
8-K
| Quarterly results |
03/10/2021 |
FOSL
|
8-K
| Quarterly results |
11/30/2020 |
BNKL
|
8-K
| Appointed CFO |
11/17/2020 |
SBH
|
8-K
| Appointed CFO |
07/02/2020 |
AFI
|
8-K
| Quarterly results |
05/01/2020 |
HPTY
|
8-K
| Appointed CFO |
04/15/2020 |
MHK
|
8-K
| Appointed CFO |
01/30/2020 |
SPR
|
8-K
| Appointed CFO |
11/07/2019 |
DXYN
|
8-K
| Appointed CFO |
09/16/2019 |
SSC
|
8-K
| Appointed CFO |
09/09/2019 |
OMQS
|
8-K
| Quarterly results |
07/23/2019 |
EVSI
|
8-K
| Appointed CFO |
|
|
|